Vaginal atrophy. Postmenopausal atrophic vaginitis
Conditions
Interventions
Intervention 1: Intervention group: Vaginal cream 5. urtica dioica plant made in the pharmacology department of medicinal plants of Mashhad University of Medical Sciences, for 8 weeks, the first 2 wee
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
45 Years to 60 Years
Inclusion criteria
Inclusion criteria: Iranian and resident of gorgan Satisfaction to participate in the study Literacy for reading and writing Married and sexually active in the past 6 months Normal menopause Age 45-60 Normal pap smear Diagnosis of vaginal atrophy (score of 4 or more on the vaginal atrophy questionnaire and vaginal PH greater than 5 and VMV equal to or less than 55)
Exclusion criteria
Exclusion criteria: Use of phytoestrogens (soy, flaxseed, red clover, fennel, nettle) one month before the start of the study Hormone therapy for 6 months before the start of the study Abnormal vaginal bleeding (spotting, pink or brown discharge, or obvious bleeding) Specific medical diseases (history of ovarian, breast and endometrial cancer - cardiovascular disease - history of thromboembolism or thrombophlebitis - history of coagulation diseases - history of ischemic stroke - migraine headaches - seizures - uterine leiomyoma - endometriosis - hypertension - diabetes - hyperlipidemia- liver and gallbladder disease - chronic kidney disease - tobacco use history - genitourinary abnormalities (uterine unicorn, bicornuate, double and septate) Use of certain medications (hormonal medications - moisturizers and vaginal gels - antihypertensive drugs - diuretics - antidepressants - antipsychotics - lithium - antihistamines - barbiturates - narcotics - benzodiazepines - hallucinogens - amphetamine – cocaine- digoxin) Vaginal infections (candida-trichomonas-bacterial vaginosis-std-herpes) History of estrogen sensitivity (breast pain, breast tenderness and sensation, spotting, itching, burning, redness) History of nettle sensitivity
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mental symptoms of vaginal atrophy. Timepoint: Before the study, 4 and 8 weeks after the intervention. Method of measurement: Vaginal assessment scale.;Vaginal PH. Timepoint: Before the study, 4 and 8 weeks after the intervention. Method of measurement: PH-indicator strips.;Vaginal maturation index. Timepoint: Before the study, 4 and 8 weeks after the intervention. Method of measurement: Pathological examination.;Vaginal maturation value. Timepoint: Before the study, 4 and 8 weeks after the intervention. Method of measurement: Pathological examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| The sexual quality of life. Timepoint: Before the study, 4 and 8 weeks after the intervention. Method of measurement: The sexual quality of life female questionaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNahid Nazari
Mashhad University of Medical Sciences
Outcome results
None listed